This trial is suspended!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Fragile X Syndrome
and you are
between 18 and 50
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The study will consist of a Screening period (up to 14 days), a Treatment period, and a Follow-Up period. Sixteen subjects will be enrolled into two sequential dose cohorts - 10 or 30 mg (or matching placebo) across four study centers.

Provided treatments

  • Drug: STX107

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01325740. The sponsor of the trial is Seaside Therapeutics, Inc. and it is looking for 16 volunteers for the current phase.
Official trial title:
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of STX107 in Adults With Fragile X Syndrome